18:10 , Oct 6, 2017 |  BC Week In Review  |  Financial News

Spectrum raises $90.2M in at-the-market offering

On Sept. 29, Spectrum Pharmaceuticals Inc. (NASDAQ:SPPI) said it raised $90.2 million since Aug. 11 in an at-the-market offering through the sale of about 9.3 million shares. Last year, Spectrum received a complete response letter...
21:56 , Sep 29, 2017 |  BC Extra  |  Financial News

Spectrum raises $90M in at-the-market offering

Spectrum Pharmaceuticals Inc. (NASDAQ:SPPI) said it raised $90.2 million since Aug. 11 in an at-the-market offering through the sale of about 9.3 million shares. Last year, Spectrum received a complete response letter from FDA for...
22:20 , Jan 6, 2017 |  BioCentury  |  Finance

Tiers of disappointment

A bad year for biotech was closed with an even worse 4Q16 as volatility ahead of the U.S. elections and continued concerns around drug pricing held every market cap band in the red despite a...
22:05 , Dec 16, 2016 |  BioCentury  |  Regulation

Blip or dip?

In a ritual held each year a couple of weeks before the winter solstice, pundits pore over FDA’s new drug approval statistics and use them to pontificate about the health of the biopharma industry and...
00:33 , Dec 2, 2016 |  BC Week In Review  |  Clinical News

Qapzola regulatory update

FDA issued a complete response letter to Spectrum for Qapzola apaziquone to treat non-muscle invasive bladder cancer (NMIBC). Based on discussions with the agency, Spectrum is considering a new smaller study of Qapzola that would...
22:49 , Nov 18, 2016 |  BC Extra  |  Company News

Complete response letter for Spectrum's Qapzola

Spectrum Pharmaceuticals Inc. (NASDAQ:SPPI) said it received a complete response letter from FDA for its non-muscle invasive bladder cancer (NMIBC) candidate Qapzola apaziquone. Based on discussions with the agency, Spectrum is considering a new smaller...
07:00 , Oct 3, 2016 |  BioCentury  |  Finance

ASH and others

Cancer and hematology companies are likely to garner the most headlines in 4Q16 thanks to ESMO in October and ASH in December, but some investors also are branching out to events that typically receive less...
07:00 , Sep 26, 2016 |  BC Week In Review  |  Clinical News

Qapzola apaziquone regulatory update

FDA’s Oncologic Drugs Advisory Committee (ODAC) voted 14-0 that Qapzola apaziquone from Spectrum has not shown substantial efficacy over placebo in treating non-muscle invasive bladder cancer (NMIBC) following transurethral resection of bladder tumors (TURBT). The...
07:00 , Jul 11, 2016 |  BioCentury  |  Finance

Rethinking risk

Steve Edelson, Senior Editor   The second half does not contain the high-impact, sector-moving milestones seen in the first six months of the year, but investors still have at least 90 late-stage milestones from which...
08:00 , Feb 22, 2016 |  BC Week In Review  |  Clinical News

Apaziquone regulatory update

FDA accepted for review an NDA from Spectrum for EOquin apaziquone to treat non-muscle invasive bladder cancer (NMIBC). The PDUFA date is Dec. 11. EOquin is an analog of mitomycin C that is reduced by...